Profile
| Role | Insider |
|---|---|
| Notability | 20/100 |
Board memberships
- Enliven Therapeutics, Inc.
- Oric Pharmaceuticals, Inc.
Updated Jul 16, 2026
Heyman Richard A. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $672K.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-08 | ORIC | Oric Pharmaceuticals, Inc. | S — Open-market sale | 300 | $12.00 | $4K |
| 2026-02-19 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.2K | $26.18 | $32K |
| 2026-01-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 718 | $26.96 | $19K |
| 2026-01-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 512 | $26.46 | $14K |
| 2026-01-21 | ORIC | Oric Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 3.2K | $12.00 | $38K |
| 2026-01-21 | ORIC | Oric Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 3.5K | $12.00 | $42K |
| 2026-01-12 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 4.3K | $25.00 | $107K |
| 2026-01-12 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 8.0K | $25.04 | $201K |
| 2026-01-12 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.6K | $25.00 | $40K |
| 2025-10-03 | ORIC | Oric Pharmaceuticals, Inc. | M — Option exercise | 1.4K | $3.75 | $5K |
| 2025-10-03 | ORIC | Oric Pharmaceuticals, Inc. | M — Option exercise | 31.4K | $1.60 | $50K |
| 2024-10-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 753 | $30.00 | $23K |
| 2024-10-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 817 | $30.00 | $25K |
| 2024-10-17 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.3K | $27.67 | $35K |
| 2024-10-08 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.8K | $27.51 | $78K |
| 2024-10-03 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 518 | $27.54 | $14K |
Heyman Richard A. is a corporate insider — currently tracked as Insider of Oric Pharmaceuticals, Inc. (ORIC). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 14 open-market sales ($672K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Heyman Richard A. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.